

Fortress Biotech Reports Financial Results for the Second Quarter 2015 Ended June 30, 2015

NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) announces its financial results for the second quarter ended June 30, 2015.

"This was another exciting quarter as we continued to make progress on executing our business plan of becoming a diversified biopharmaceutical company with a robust pipeline of products and multiple potential revenue streams," said Dr. Lindsay A. Rosenwald, Fortress Biotech's Chairman, President and CEO. "Our plan is to continue to develop and commercialize the products that we have acquired either within Fortress, or through our Fortress Companies. We operate in a robust market and we will seek licensing, partnerships, joint ventures and outside financings to support our research and development programs in 2015 and beyond."

During the second quarter and the subsequent few weeks, Fortress Biotech secured a licensing agreement through Altamira Bio, a subsidiary focused on the clinical development and commercialization of therapies for orphan/rare diseases. Altamira Bio acquired from New Zealand Pharmaceuticals Ltd (NZP), a license and Cooperative Research and Development Agreements (CRADAs) from the National Institutes of Health (NIH) for the development of oral N-acetyl-D-mannosamine (ManNAc), a key compound in the sialic acid biosynthetic pathway, for the treatment of hyposialylation disorders such as HIBM (GNE Myopathy) and nephropathies. The Cooperative Research and Development Agreements from the NIH include the National Human Genome Research Institute (NHGRI), National Center for Advancing Translational Sciences (NCATS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Financial Highlights:

- At June 30, 2015, Fortress Biotech's net cash and marketable securities totaled \$61.0 million compared to \$68.9 million at March 31, 2015 and \$69.8 million at December 31, 2014, a decrease of \$7.9 million for the quarter and a decrease of \$8.8 million year-to-date; this total excludes restricted cash of \$14.6 million.
- License acquisitions totaled \$1.5 million and \$9.0 million for the three and six months ended June 30, 2015, respectively.
- Research and development expenses were \$2.4 million and \$4.1 million for the three and six months ended June 30, 2015, respectively.

- General and administrative expenses were \$3.8 million and \$7.3 million for the three and six months ended June 30, 2015, respectively.
- Quarterly net loss was \$6.2 million and \$18.2 million, or \$0.16 and \$0.47 per share, for the three and six months ended June 30, 2015 respectively, compared to a quarterly net loss of \$4.7 million and \$12.1 million, or \$0.13 and \$0.34 per share for the three and six months ended June 30, 2014, respectively.

About Fortress Biotech

Fortress Biotech, Inc. ("Fortress" or "the Company") is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products both within Fortress and within subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, the Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company will provide funding and management services to each of the Fortress Companies and, from time to time, the Company and the Fortress Companies will seek licensing, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds: government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(\$ in thousands)

Name Commitments and contingencies Commitments and conti		2015	2014
Current assets \$41,037 \$49,759 Marketable securities, at fair value 20,000 20,000 Prepaid expenses and other current assets 997 702 Total current assets 62,034 70,463 Property and equipment, net 80 55 Restricted cash 14,586 14,586 Long-term investments, at fair value 5,567 4,160 Intangible asset - license 1,250 - Other assets 3172 64 Total assets 83,569 \$83,569 Cover assets 4,360 3,863 Interest payable \$5,83 \$366 Interest payable \$5,83 \$368 Accounts payable \$5,83 \$369 Interest payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 268 72 Commitments and contingencies 28,491 18,002 Stockholders' equily 20,201 <th></th> <th>(Unaudited)</th> <th></th>		(Unaudited)	
Cash and cash equivalents \$41,037 \$49,759 Marketable securities, at fair value 20,000 20,002 Prepaid expenses and other current assets 997 702 Total current assets 62,034 70,463 Property and equipment, net 99 52 Restricted cash 14,586 14,586 Long-term investments, at fair value 12,567 4,160 Intangible asset - license 12,250 Other assets 172 64 Total assets \$83,699 \$83,259 LAGABILITIES AND STOCKHOLDERS' EQUITY Variabilities 55,83 \$366 Accounts payable 5 5 3,863 1,962 28 Accounts payable 5 2,83 3,683 1,962 28 Accounts payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively 23,232 14,003 Other long-term liabilities 28,491 18,002 14,003 Commitments and contingencies 28,491 18,002 Stockholders' equity<	ASSETS		
Marketable securities, at fair value 20,000 Prepaid expenses and other current assets 997 702 Total current assets 62,004 70,465 Property and equipment, net 90 52 Restricted cash 14,568 14,568 Long-term investments, at fair value 5,567 4,168 Intangible asset -license 125 6 Other assets 172 66 Total assets 833,699 833,699 Interest payable 5,583 \$366 Interest payable 2,6 28 Accounts payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 28,49 18,003 Total laibilities 28,49 18,003 Commitments and contingencies 28,232 14,003 Commitments and contingencies 28,49 18,003 Commitments and contingencies 21,57 21 Commitments and contingencies 21,57 21 Commitments and contingencies<	Current assets		
Prepaid expenses and other current assets 99 (20) Total current assets 62,034 70,463 Property and equipment, net 9 52 Restricted cash 14,586 14,586 Long-term investments, at fair value 5,567 4,160 Intangible asset - license 120 -6 Other assets 177 6 Cother assets 177 6 Current liabilities 83,369 89,325 Accounts payable 26 28 Accouded expenses 4,396 3,683 Total current liabilities 4,995 4,072 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 26 722 Total liabilities 28,491 18,002 Commitments and contingencies 25,491 18,002 Stockholders' equity - - - Commitments and contingencies - - - Stockholders' equity - -<	Cash and cash equivalents	\$ 41,037	\$ 49,759
Total current assets 62.034 70.463 Property and equipment, net 90 52 Restricted cash 14.586 14.586 Long-term investments, at fair value 5.567 4.160 Intangible asset - license 1.250 Other assets 172 64 Total assets \$83,699 \$89,325 LIABILITIES AND STOCKHOLDERS' EQUITY Total assets \$83,699 \$89,325 Accounts payable \$6 28 \$36 \$66 Interest payable 26 28 \$36 \$66 186 186 3683 \$366 186 3683 \$366 186 3683 \$366 186 3683 \$366 186 3683 \$366 3683 3683 366 3683 3683 366 3683 3683 366 3683 3664 3683 3666 3683 3666 3683 3666 3683 3666 3683 3666 3683 3666 3683 3666 36	Marketable securities, at fair value	20,000	20,002
Property and equipment, net 90 52 Restricted cash 14,566 14,566 Long-term investments, at fair value 5,567 4,160 Intanapible asset - license 1,250 - Other assets 172 64 Total assets \$83,699 \$89,325 LIABILITIES AND STOCKHOLDERS' EQUITY Value Value Current liabilities 4 26 28 Accounts payable 5583 \$366 186 188 3683 Total current liabilities 26 28 4,386 3,683 3	Prepaid expenses and other current assets	997	702
Restricted cash 14,586 14,586 Long-term investments, at fair value 5,567 4,160 Intangible asset - license 1,250 - Other assets 1772 64 Total assets \$83,699 \$89,325 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities \$583 \$366 Current liabilities \$583 \$586 \$66 26 28 Accrued expenses 4,386 3,686	Total current assets	62,034	70,463
Congress Ficense Fic	Property and equipment, net	90	52
1,250 1,25	Restricted cash	14,586	14,586
Other assets 172 64 Total assets \$83,699 \$89,325 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable \$583 \$366 Interest payable 26 28 Accrued expenses 4,386 3,683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies 25,491 18,802 Stockholders' equity - - Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and cutstanding as of June 30, 2015 and December 31, 2014, respectively - - Convertible Preferred stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,203 12,205 Accumulated defi	Long-term investments, at fair value	5,567	4,160
Total assets \$ 83,699 \$ 89,325 LIABILITIES AND STOCKHOLDERS' EQUITY \$ 500	Intangible asset - license	1,250	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities \$583 \$366 Accounts payable 26 28 Accrued expenses 4,386 3,683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies 5 5 Stockholders' equity - Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest 55,208 70	Other assets	172	64
Current liabilities \$583 \$366 Interest payable 26 28 Accrued expenses 4,386 3,683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies 5 5 Stockholders' equity - - Common Stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) - Total stockholders' equity 55,208 7	Total assets	\$ 83,699	\$ 89,325
Accounts payable \$ 583 \$ 366 Interest payable 26 28 Accrued expenses 4,386 3.683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies Stockholders' equity - - Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) - Total stockholders' equity - -	LIABILITIES AND STOCKHOLDERS' EQUITY		
Interest payable 26 28 Accrued expenses 4,366 3,683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies 5 25,249 18,802 Comvertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) - Total stockholders' equity 555,208 70,523	Current liabilities		
Accrued expenses 4,386 3,683 Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Stockholders' equity - - Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) - Total stockholders' equity 555,208 70,523	Accounts payable	\$ 583	\$ 366
Total current liabilities 4,995 4,077 Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Commitments and contingencies Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company Non-controlling interest (673) — Total stockholders' equity Total stockholders' equity	Interest payable	26	28
Notes payable, long-term, net (net of debt discount of \$777 and \$6 at June 30, 2015 and December 31, 2014, respectively) Other long-term liabilities 264 722 Total liabilities 284 18,802 Commitments and contingencies Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Additional paid-in-capital Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) — Total stockholders' equity	Accrued expenses	4,386	3,683
2014, respectively) 23,232 14,003 Other long-term liabilities 264 722 Total liabilities 28,491 18,802 Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) - Total stockholders' equity 55,208 70,523	Total current liabilities	4,995	4,077
Other long-term liabilities264722Total liabilities28,49118,802Stockholders' equityConvertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectivelyCommon Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively4746Additional paid-in-capital215,793212,205Accumulated deficit(159,959)(141,728)Total stockholders' equity attributed to the Company55,88170,523Non-controlling interest(673)-Total stockholders' equity55,20870,523			
Total liabilities 28,491 18,802 Commitments and contingencies Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity attributed to the Company Non-controlling interest Total stockholders' equity Total stockholders' equity Total stockholders' equity Total stockholders' equity		•	•
Commitments and contingencies Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) —- Total stockholders' equity Total stockholders' equity			
Stockholders' equity Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) — Total stockholders' equity 40,000 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523	Total liabilities	28,491	18,802
Convertible Preferred stock, \$.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Additional paid-in-capital Accumulated deficit Company Company Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital Company Company	Commitments and contingencies		
outstanding as of June 30, 2015 and December 31, 2014, respectively Common Stock, \$.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 47 46 Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) Total stockholders' equity 40,523 70,523	Stockholders' equity		
Additional paid-in-capital 215,793 212,205 Accumulated deficit (159,959) (141,728) Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest (673) Total stockholders' equity 40,523			
Accumulated deficit Total stockholders' equity attributed to the Company Non-controlling interest Total stockholders' equity		47	46
Total stockholders' equity attributed to the Company 55,881 70,523 Non-controlling interest Total stockholders' equity 55,208 70,523	Additional paid-in-capital	215,793	212,205
Non-controlling interest Total stockholders' equity (673) 55,208 70,523	Accumulated deficit	(159,959)	(141,728)
Total stockholders' equity 55,208 70,523	Total stockholders' equity attributed to the Company	55,881	70,523
Total stockholders' equity 55,208 70,523	Non-controlling interest	(673)	
4.00.000	Total stockholders' equity	55,208	70,523
	Total liabilities and stockholders' equity	\$ 83,699	\$ 89,325

FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Condensed Consolidated Statement of Operations
(\$ in thousands except for share and per share amounts)
(Unaudited)

	For the three months ended June 30,		For the six months ended June 30,	
	2015	2014	2015	2014
Revenue	\$	\$	\$ 500	\$
Operating expenses				
Research and development	2,411	2,377	4,066	6,865
Research and development – licenses acquired	1,548		8,987	
General and administrative	3,803	2,386	7,280	4,481
Total operating expenses	7,762	4,763	20,333	11,346
Loss from operations	(7,762)	(4,763)	(19,833)	(11,346)
Other income (expenses)				
Interest income	74	171	156	350
Interest expenses	(352)	(119)	(683)	(1,085)
Change in fair value of investments	1,622		1,407	
Total other income (expenses)	1,344	52	880	(735)
Net loss	(6,418)	(4,711)	(18,953)	(12,081)
Less: net loss attributable to non-controlling interest	243		722	
Net loss attributable to common stockholders	\$ (6,175)	\$ (4,711)	\$ (18,231)	\$ (12,081)
Basic and diluted net loss per common share	\$ (0.16)	\$ (0.13)	\$ (0.47)	\$ (0.34)
Weighted average common shares outstanding—basic and diluted	39,119,606	36,005,294	38,848,660	35,953,234

CONTACT: Lucy Lu, MD, Executive Vice President &

Chief Financial Officer Fortress Biotech, Inc.

781-652-4525; ir@fortressbiotech.com

Source: Fortress Biotech, Inc.